Under a high-dose DMBA (100 nmol) and TPA (10 nmol) treatment, TCF7L1-induced mice developed a greater number of papillomas at a faster rate than control mice did (Figure 2B,C; n = 17 TCF7L1-induced, n = 16 control). Here, TCF7L1 is linked to papilloma.